ストックスクリーナーアプリを入手
0.9699
4.16%
0.0387
前日終値:
$0.9312
開ける：
$0.9401
24時間の取引高:
20.97M
Relative Volume:
5.47
時価総額：
$285.74M
収益：
$55.87M
当期純損益:
$-77.60M
株価収益率:
-2.7191
EPS:
-0.3567
ネットキャッシュフロー:
$-79.46M
1週間 パフォーマンス:
+19.37%
1か月 パフォーマンス:
-14.17%
6か月 パフォーマンス:
-57.65%
1年 パフォーマンス:
+29.49%
1日の値動き範囲:
$0.902
$1.01
1週間の範囲:
$0.7282
$1.01
52週間の値動き範囲:
$0.483
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Compare IVVD vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.9699 | 285.74M | 55.87M | -77.60M | -79.46M | -0.3567 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-22 | 開始されました | BTIG Research | Buy |
| 2025-11-25 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2025-10-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-04-05 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-03-26 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Invivyd Inc (IVVD) 最新ニュース
Invivyd (IVVD) Doses First Participants in Phase 3 Trial for VYD2311 - Insider Monkey
Invivyd Inc (IVVD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Invivyd Inc (IVVD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Invivyd Inc (IVVD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Invivyd Inc (IVVD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Invivyd Inc (IVVD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Invivyd Inc (IVVD) Institutional Confidence - TradingKey
Invivyd Inc (IVVD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Invivyd Inc (IVVD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Invivyd Inc (IVVD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Invivyd completes Phase 3 COVID-19 antibody trial enrollment - grafa.com
Invivyd's Late-Stage Trial of Covid Vaccine Alternative Completes Enrollment; Shares Rise Pre-Bell - Moomoo
Invivyd completes enrollment in Phase 3 COVID antibody trial By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Invivyd stock rating on trial progress - Investing.com
Invivyd completes enrollment in Phase 3 COVID antibody trial - Investing.com
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine - The Manila Times
Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Rezolute (RZLT) and Invivyd (IVVD) - The Globe and Mail
IVVD Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
IVVD Stock Quote Price and Forecast - CNN
Invivyd doses first participants in phase 3 COVID-19 trial of VYD2311 - Contagion Live
Invivyd Inc (IVVD) Reports Clinical Progress. Stock Expected to Explode - Insider Monkey
Billionaire Lee Ainslie’s 10 Stocks with Huge Upside Potential - Insider Monkey
IVVD,VCEL Revenue Breakdown - Finviz
IVVD Reiterated by BTIG -- Price Target Maintained at $10 - GuruFocus
Invivyd doses first participants in Phase 3 COVID-19 trial - Yahoo! Finance Canada
Invivyd doses first participants in Phase 3 LIBERTY trial - grafa.com
Small cap wrap: Royal Road Minerals, Miivo Holdings, Alvopetro, Arizona Gold & Silver... - Proactive financial news
Invivyd doses first participants in COVID-19 vaccine trial By Investing.com - Investing.com Australia
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-A - The Manila Times
Invivyd doses first participants in COVID-19 vaccine trial - Investing.com
New COVID shot alternative faces off with mRNA vaccine in Invivyd trial - Stock Titan
InvivydExpects Liberty Trial Topline Data In Q3 2026 - TradingView
We Think Invivyd (NASDAQ:IVVD) Can Afford To Drive Business Growth - Moomoo
InVivo Therapeutics Holdings Corp (NVIV) - Minichart
This Invivyd Insider Increased Their Holding In The Last Year - Yahoo Finance
INVIVYD INC (IVVD) Stock Chart - ChartMill
IVVD News | INVIVYD INC (NASDAQ:IVVD) - ChartMill
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Invivyd offers stock options to 17 new hires at $1.22 each - Stock Titan
Invivyd Shareholder Notice - TMX Newsfile
Invivyd Inc stock (US46186M1080): focus on upcoming Jefferies conference and COVID-19 prevention tri - AD HOC NEWS
Invivyd Shareholder Action Reminder - TMX Newsfile
IVVD Reiterated by BTIG -- Price Target Maintained at $10.00 - GuruFocus
Invivyd completes enrollment in COVID-19 prevention trial - Investing.com UK
Invivyd completes enrollment in COVID-19 prevention trial By Investing.com - Investing.com Australia
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID - The Manila Times
Invivyd Announces Completion of Enrollment in Phase 3 DECLARATION Trial for VYD2311 in COVID-19 Prevention - Quiver Quantitative
COVID antibody trial fully enrolled as Invivyd targets Q3 2026 results - Stock Titan
Invivyd Q1 2026 earnings preview - MSN
Invivyd Inc (IVVD) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):